Table 3.
The prognostic value of CD44 and CD44+CD24-/low phenotype in TNBC patients.
| First author, year | Endpoint | Number of patients | Studied factor | Prognostic value | HR, CI 95%, and P-value | Follow-up time | Previous treatment |
|---|---|---|---|---|---|---|---|
| Francesca Collina, ( 25 ) | DFS | 143 | CD44 | Its overexpression is associated with worse DFS. | Not provided | About 90 months | N/A |
| Fang Yang, ( 26 ) | PFS | 88 | CD44+CD24-/low | It is not statistically associated with PFS. | 1.74, (0.73-4.13), and 0.211 | 72 months | Eighty-two patients were on adjuvant chemotherapy. |
| Yan−Xi Liu, ( 27 ) | RFS | 123 | CD44+CD24-/low | It is not statistically associated with RFS. | 2.17, (0.76−2.74), and 0.006 | 68 monthes | With chemotherapy |
| Yan−Xi Liu, ( 27 ) | Breast cancer-specific survival | 123 | CD44+CD24-/low | It is not statistically associated with breast cancer-specific survival. | 2.30, (0.95−2.84), and 0.003 | 68 months | With chemotherapy |
| Yan−Xi Liu, ( 27 ) | RFS | 31 | CD44+CD24-/low | It is not statistically associated with RFS. | 1.68, (1.14−3.07), and 0.115 | 68 months | No previous chemotherapy |
| Yan−Xi Liu, ( 27 ) | Breast cancer-specific survival | 31 | CD44+CD24-/low | It is not statistically associated with breast cancer-specific survival. | 1.72, (0.88−2.74), and 0.092 | 68 months | No previous chemotherapy |
| Hui Wang, ( 28 ) | DFS | 145 | CD44+CD24-/low | It is not statistically associated with DFS. | 2.38, (0.90−6.33), and 0.081 | 76 months | None of the patients were on targeted therapy, radiotherapy, chemotherapy, and adjuvant endocrine treatment. |
| Hui Wang, ( 28 ) | OS | 145 | CD44+CD24-/low | It is associated with OS. | 4.38, (1.57−12.18), and 0.005 | 76 months | None of the patients were on targeted therapy, radiotherapy, chemotherapy, and adjuvant endocrine treatment. |
| Weiyan Zou, ( 29 ) | OS | 51 | CD44+CD24-/low | Regardless of lymph node metastasis, it is associated with OS. | Not provided | About 70 months | N/A |
| Weiyan Zou, ( 29 ) | DFS | 51 | CD44+CD24-/low | Regardless of lymph node metastasis, it is associated with DFS. | Not provided | About 70 months | N/A |
DFS, disease-free survival; PFS, progression-free survival; RFS, relapse-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval.